Three IP-related laws and policies have been released for public comment in the past week, at two different stages in the legislative process. The first and perhaps most significant is the revisions […]
Three Laws/Policies Up For Public Comment
CFDA’s New Policies to Promote IP and Innovation in the Pharma Sector
As noted previously in this blog, the death of patent linkage which had been heralded by draft Drug Registration Rules appears to be premature. In fact, the China Food and Drug Administration […]
More Policy Discussions on Pharma IP Reform
There appear to be some serious discussion of late regarding China using its IP laws to encourage more innovative drugs. One significant advance was the recent amendments to China’s Patent Examination Guidelines […]
China IPR - Intellectual Property Developments in China 